NO20091266L - Fremgangsmåter for administrering av langvarige hypoglykemiske midler - Google Patents

Fremgangsmåter for administrering av langvarige hypoglykemiske midler

Info

Publication number
NO20091266L
NO20091266L NO20091266A NO20091266A NO20091266L NO 20091266 L NO20091266 L NO 20091266L NO 20091266 A NO20091266 A NO 20091266A NO 20091266 A NO20091266 A NO 20091266A NO 20091266 L NO20091266 L NO 20091266L
Authority
NO
Norway
Prior art keywords
term
methods
hypoglycaemic agents
administering long
administering
Prior art date
Application number
NO20091266A
Other languages
English (en)
Inventor
Mark A Bush
Jessica E Matthews
Susan E Walker
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of NO20091266L publication Critical patent/NO20091266L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20091266A 2006-09-13 2009-03-26 Fremgangsmåter for administrering av langvarige hypoglykemiske midler NO20091266L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US82547206P 2006-09-13 2006-09-13
US86839106P 2006-12-04 2006-12-04
PCT/US2007/078226 WO2008033888A2 (en) 2006-09-13 2007-09-12 Methods for administering long-lasting hypoglycemic agents

Publications (1)

Publication Number Publication Date
NO20091266L true NO20091266L (no) 2009-06-09

Family

ID=39184534

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20091266A NO20091266L (no) 2006-09-13 2009-03-26 Fremgangsmåter for administrering av langvarige hypoglykemiske midler

Country Status (25)

Country Link
US (3) US8338369B2 (no)
EP (1) EP2073834B1 (no)
JP (2) JP5524620B2 (no)
KR (1) KR101472601B1 (no)
CN (1) CN103705911A (no)
AR (1) AR062775A1 (no)
AU (1) AU2007296499C1 (no)
BR (1) BRPI0716765A8 (no)
CA (1) CA2662622C (no)
CL (1) CL2007002634A1 (no)
CR (1) CR10684A (no)
EA (1) EA017159B1 (no)
ES (1) ES2442869T3 (no)
IL (1) IL197448A (no)
JO (1) JO2945B1 (no)
MA (1) MA30768B1 (no)
MX (1) MX2009002863A (no)
MY (1) MY149911A (no)
NO (1) NO20091266L (no)
NZ (1) NZ575419A (no)
PE (2) PE20080840A1 (no)
SG (2) SG174770A1 (no)
TW (1) TWI430806B (no)
WO (1) WO2008033888A2 (no)
ZA (1) ZA200901548B (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE029798T2 (en) 2005-11-04 2017-03-28 Glaxosmithkline Llc Methods of administering hypoglycemic agents
DK2373681T3 (en) * 2008-12-10 2017-04-24 Glaxosmithkline Llc PHARMACEUTICAL COMPOSITIONS OF ALBIGLUTID
JP2013525491A (ja) 2010-05-04 2013-06-20 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 心血管障害を治療または予防し心血管保護を提供する方法
PL2651398T3 (pl) 2010-12-16 2018-05-30 Novo Nordisk A/S Stałe kompozycje zawierające agonistę GLP-1 i sól kwasu N-(8-(2-hydroksybenzoilo)amino)kaprylowego
DK2696687T3 (en) 2011-04-12 2017-02-06 Novo Nordisk As Double-acylated GLP-1 derivatives
HUE042757T2 (hu) 2012-03-22 2019-07-29 Novo Nordisk As Szállító szert tartalmazó készítmények és elõállításuk
EP4324475A1 (en) 2012-03-22 2024-02-21 Novo Nordisk A/S Compositions of glp-1 peptides and preparation thereof
JP6517690B2 (ja) 2012-06-20 2019-05-22 ノヴォ ノルディスク アー／エス ペプチド及び送達剤を含む錠剤製剤
KR20210086717A (ko) * 2013-05-02 2021-07-08 노보 노르디스크 에이/에스 Glp-1 화합물의 경구 투여
AR096440A1 (es) 2013-05-28 2015-12-30 Takeda Pharmaceuticals Co Compuesto peptídico agonista del receptor del péptido similar al glucagón tipo i (glp-1) y del péptido insulinotrópico dependiente de glucosa (gip)
EP3467106B1 (en) 2016-05-24 2025-07-09 Takeda Pharmaceutical Company Limited Peptide compound
WO2019149880A1 (en) 2018-02-02 2019-08-08 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant
TW202423476A (zh) * 2021-03-23 2024-06-16 美商美國禮來大藥廠 含腸促胰島素(incretin)類似物之組合物及其用途

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545618A (en) * 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
US5512549A (en) * 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
DE69739172D1 (de) * 1996-08-08 2009-01-29 Amylin Pharmaceuticals Inc Regulation gastrointestinaler beweglichkeit
US6277819B1 (en) * 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
US6380357B2 (en) * 1997-12-16 2002-04-30 Eli Lilly And Company Glucagon-like peptide-1 crystals
HUP0103369A3 (en) * 1998-08-28 2002-03-28 Lilly Co Eli Use of insulinotropic peptides
SI1180121T1 (en) * 1999-05-17 2004-04-30 Conjuchem, Inc. Long lasting insulinotropic peptides
US6395767B2 (en) * 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
ES2311560T3 (es) * 2000-12-07 2009-02-16 Eli Lilly And Company Proteinas de fusion glp-1.
EP2186824A3 (en) * 2000-12-13 2010-09-22 Eli Lilly & Company Chronic treatment regimen using glucagon-like insulinotropic peptides
JP2005506956A (ja) * 2001-06-01 2005-03-10 イーライ・リリー・アンド・カンパニー 長時間作用性ｇｌｐ−１製剤
CA2458371A1 (en) * 2001-08-23 2003-03-06 Eli Lilly And Company Glucagon-like peptide-1 analogs
AR036711A1 (es) 2001-10-05 2004-09-29 Bayer Corp Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico
KR20040054729A (ko) 2001-10-18 2004-06-25 브리스톨-마이어스 스큅 컴퍼니 인간 글루카곤-유사-펩티드-1 모방체, 및 당뇨병 및 이와관련된 증상의 치료에 있어서 이의 용도
PT1463751E (pt) * 2001-12-21 2013-08-26 Human Genome Sciences Inc Proteínas de fusão de albumina
EP1463752A4 (en) * 2001-12-21 2005-07-13 Human Genome Sciences Inc ALBUM INFUSION PROTEINS
BR0306706A (pt) * 2002-01-08 2007-03-27 Lilly Co Eli peptìdeo glp-1 estendido, métodos de estimulação do receptor de glp-1 em um indivìduo necessitando de normalização de glicose sanguìnea, de tratamento de um indivìduo profilaticamente para diabetes independente de insulina, de redução ou de manutenção do peso corporal, de tratamento da obesidade, e de tratamento de doenças, em um indivìduo necessitando do mesmo, uso de um composto de glp-1, processo de preparação de uma formulação farmacêutica, e, formulação farmacêutica
CA2513213C (en) * 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
EP1689757B1 (en) * 2003-11-12 2014-08-27 Phenomix Corporation Heterocyclic boronic acid compounds
JP4697596B2 (ja) * 2004-01-13 2011-06-08 旭硝子株式会社 多層積層体
JP5010923B2 (ja) * 2004-02-09 2012-08-29 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド アルブミン融合蛋白質
EP1758575A1 (en) * 2004-06-11 2007-03-07 Novo Nordisk A/S Counteracting drug-induced obesity using glp-1 agonists
HUE029798T2 (en) * 2005-11-04 2017-03-28 Glaxosmithkline Llc Methods of administering hypoglycemic agents
WO2007139589A1 (en) 2006-05-26 2007-12-06 Bristol-Myers Squibb Company Sustained release glp-1 receptor modulators

Also Published As

Publication number Publication date
TWI430806B (zh) 2014-03-21
BRPI0716765A2 (pt) 2013-09-24
EP2073834A2 (en) 2009-07-01
EP2073834A4 (en) 2010-11-03
EA200970274A1 (ru) 2009-08-28
JP2014148524A (ja) 2014-08-21
AR062775A1 (es) 2008-12-03
US20100009910A1 (en) 2010-01-14
SG10201501749WA (en) 2015-05-28
CL2007002634A1 (es) 2008-05-16
CA2662622C (en) 2017-01-17
MA30768B1 (fr) 2009-10-01
PE20121528A1 (es) 2012-12-12
SG174770A1 (en) 2011-10-28
BRPI0716765A8 (pt) 2017-02-21
MX2009002863A (es) 2009-03-30
US20140066371A1 (en) 2014-03-06
MY149911A (en) 2013-10-31
AU2007296499A1 (en) 2008-03-20
CR10684A (es) 2009-04-28
KR20090059155A (ko) 2009-06-10
JP5524620B2 (ja) 2014-06-18
AU2007296499B2 (en) 2013-05-02
WO2008033888A2 (en) 2008-03-20
CN103705911A (zh) 2014-04-09
ES2442869T3 (es) 2014-02-14
TW200824706A (en) 2008-06-16
PE20080840A1 (es) 2008-08-27
EA017159B1 (ru) 2012-10-30
NZ575419A (en) 2011-11-25
IL197448A0 (en) 2011-08-01
KR101472601B1 (ko) 2014-12-15
IL197448A (en) 2013-06-27
EP2073834B1 (en) 2013-10-23
JP2010503697A (ja) 2010-02-04
US20130005652A1 (en) 2013-01-03
US8338369B2 (en) 2012-12-25
WO2008033888A3 (en) 2008-10-16
JO2945B1 (en) 2016-03-15
CA2662622A1 (en) 2008-03-20
JP5753924B2 (ja) 2015-07-22
AU2007296499C1 (en) 2013-09-12
ZA200901548B (en) 2010-02-24

Similar Documents

Publication Publication Date Title
CY2022001I1 (el) Παραγωγα του uk-2a
LTPA2016032I1 (lt) Hipoglikeminių agentų skyrimo būdai
CY2014011I2 (el) Χορηγηση αναστολεων διπεπτιδυλοπεπτιδασης
DOP2007000084A (es) Derivados de dihidropirazolopirimidinona
CR10562A (es) Nuevos derivados de piridazina
DK2474321T3 (da) Sammensætninger til behandling af collagenmedierede sygdomme
HUS1600048I1 (hu) Készítmény Fabry-kór kezelésére
LTPA2016005I1 (lt) Anti-il-5 antikūnų skyrimo būdai
BRPI0715712A2 (pt) Composição farmacêutica
DK3421471T3 (da) Purin- og deazapurinderivater som farmaceutiske forbindelser
DK1874781T3 (da) Dihydrothienopyrimidiner til behandling af inflammatoriske sygdomme
DK2073795T3 (da) Misbrugssikret lægemiddelformulation
DK2041139T3 (da) Farmaceutiske forbindelser
ATE531720T1 (de) Aza-benzofuranylverbindungen und anwendungsverfahren dafür
DK3456707T3 (da) 4-(p-quinonyl)-2-hydroxybutanamidderivater til behandling af mitokondriesygdomme
BRPI0719393A2 (pt) Composição farmacêutica
LT2478907T (lt) Kompozicijos vėžiui gydyti
LT2966175T (lt) Farmacinės kompozicijos turinčios korteksolono-17-alfa-propionato
DK1940467T3 (da) Lægemiddelsammensætning med langvarig frigivelse
CR10809A (es) Derivados de heteroaril-pirrolidinil-y-piperidinil-cetona
EP2037738A4 (en) feeding method
BRPI0716445A2 (pt) composiÇço farmacÊutica
BRPI0720234A2 (pt) Composição farmacêutica
DK2035369T3 (da) Terapeutiske
EP2041108A4 (en) 4-HYDROXYTHIOZENZAMIDE DERIVATIVES OF MEDICAMENTS

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application